Publications 2006
Brekelmans CT, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, van Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG
Survival and prognostic factors in BRCA1-associated breast cancer.
Ann Oncol. 2006 Mar;17(3):391-400
de Jonge MJ, Dumez H, Verweij J, Yarkoni S, Snyder D, Lacombe D, Marréaud S, Yamaguchi T, Punt CJ, van Oosterom A,
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
Eur J Cancer. 2006 Aug;42(12):1768-74
de Jonge MJ, Verweij J
Renal toxicities of chemotherapy.
Semin Oncol. 2006 Feb;33(1):68-73
de Jonge MJ, Verweij J
Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
Eur J Cancer. 2006 Jul;42(10):1351-6
de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH
Role of pharmacogenetics in irinotecan therapy.
Cancer Lett. 2006 Mar 8;234(1):90-106
de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, Planting AS, van der Gaast A, Eskens FA, Janssen JT, Ruit JB, Verweij J, Sparreboom A, de Jonge MJ
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
Oncologist. 2006 Sep;11(8):944-54
de Jong FA, Kitzen JJ, de Bruijn P, Verweij J, Loos WJ
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
Cancer Biol Ther. 2006 Sep;5(9):1105-10
de Wit R, Fizazi K
Controversies in the management of clinical stage I testis cancer.
J Clin Oncol. 2006 Dec 10;24(35):5482-92
Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, Schutte M
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 2006 Jan 1;66(1):41-5
Engels FK, Buijs D, Loos WJ, Verweij J, Bakker WH, Krenning EP
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method.
Anticancer Drugs. 2006 Jan;17(1):63-7
Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Cancer Biol Ther. 2006 Jul;5(7):833-9
Eskens FA, Verweij J
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
Eur J Cancer. 2006 Dec;42(18):3127-39
Felici A, Loos WJ, Verweij J, Cirillo I, de Bruijn P, Nooter K, Mathijssen RH, de Jonge MJ
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Cancer Chemother Pharmacol. 2006 Nov;58(5):673-80
Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, Cufer T, Sieuwerts AM, Talantov D, Span PN, Tjan-Heijnen VC, Zito AF, Specht K, Hoefler H, Golouh R, Schittulli F, Schmitt M, Beex LV, Klijn JG, Wang Y
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
J Clin Oncol. 2006 Apr 10;24(11):1665-71
Gratama J, Kvalheim G, Orfao A
Standardization of cell analysis methods in clinical cellular therapy programs: A challenge for ISCT.
Cytotherapy. 2006;8(6):528-9
Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K
Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Cancer Biol Ther. 2006 Aug;5(8):943-9
Helleman J, Jansen MP, Berns EM
Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification.
Int J Gynecol Cancer. 2006;16 Suppl 2:538-42
Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM
Molecular profiling of platinum resistant ovarian cancer.
Int J Cancer. 2006 Apr 15;118(8):1963-71
Helleman J, van Staveren IL, Dinjens WN, van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G, Berns EM
Mismatch repair and treatment resistance in ovarian cancer.
BMC Cancer. 2006;6:201
Hoekstra R, de Vos FY, Eskens FA, de Vries EG, Uges DR, Knight R, Carr RA, Humerickhouse R, Verweij J, Gietema JA
Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination.
Eur J Cancer. 2006 Mar;42(4):467-72
Kitzen JJ, Verweij J, Wiemer EA, Loos WJ
The relevance of microdialysis for clinical on:cology.
Curr Clin Pharmacol. 2006 Sep;1(3):255-63
Kriege M, Brekelmans CT, Boetes C, Muller SH, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Rutgers EJ, de Koning HJ, Klijn JG,
Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.
Cancer. 2006 Jun 1;106(11):2318-26
Kriege M, Brekelmans CT, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Kaas R, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, Rutgers EJ, de Koning HJ, Klijn JG
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer.
Breast Cancer Res Treat. 2006 Nov;100(1):109-19
Kriege M, Brekelmans CT, Peterse H, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, Kok T, Manoliu RA, Besnard AP, Tilanus-Linthorst MM, Seynaeve C, Bartels CC, Meijer S, Oosterwijk JC, Hoogerbrugge N, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer.
Breast Cancer Res Treat. 2007 May;102(3):357-63
Lamers CH, van Elzakker P, Langeveld SC, Sleijfer S, Gratama JW
Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
Cytotherapy. 2006;8(6):542-53
Lamers CH, Willemsen RA, van Elzakker P, van Krimpen BA, Gratama JW, Debets R
Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.
Cancer Gene Ther. 2006 May;13(5):503-9
Loos WJ, de Jongh FE, Sparreboom A, de Wit R, van Boven-van Zomeren DM, Stoter G, Nooter K, Verweij J
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
J Clin Oncol. 2006 Apr 1;24(10):1499-506
Loos WJ, de Wit R, Freedman SJ, Van Dyck K, Gambale JJ, Li S, Murphy GM, van Noort C, de Bruijn P, Verweij J
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Cancer Chemother Pharmacol. 2007 Feb;59(3):407-12
Mathijssen RH, van Schaik RH
Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.
Eur J Cancer. 2006 Jan;42(2):141-8
Meijer D, van Agthoven T, Bosma PT, Nooter K, Dorssers LC
Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells.
Mol Cancer Res. 2006 Jun;4(6):379-86
Schaft N, Lankiewicz B, Drexhage J, Berrevoets C, Moss DJ, Levitsky V, Bonneville M, Lee SP, McMichael AJ, Gratama JW, Bolhuis RL, Willemsen R, Debets R
T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.
Int Immunol. 2006 Apr;18(4):591-601
Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA
Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3319-28
Sleijfer S, Seynaeve C, Wiemer E, Verweij J
Practical aspects of managing gastrointestinal stromal tumors.
Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S18-23
Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW, Foekens JA
Genes associated with breast cancer metastatic to bone.
J Clin Oncol. 2006 May 20;24(15):2261-7
Tascilar M, de Jong FA, Verweij J, Mathijssen RH
Complementary and alternative medicine during cancer treatment: beyond innocence.
Oncologist. 2006 Jul-Aug;11(7):732-41
van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A
Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study.
Br J Cancer. 2006 May 22;94(10):1389-94
Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res Treat. 2006 Sep;99(1):97-101
Willemsen RA, Sebestyén Z, Ronteltap C, Berrevoets C, Drexhage J, Debets R
CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10.
J Immunol. 2006 Jul 15;177(2):991-8